NCT04201938View on ClinicalTrials.gov

Effect of Probiotic Co-administration With Omega-3 Fatty Acids on Obesity Parameters and Insulin Resistance

NACompletedINTERVENTIONAL
Enrollment

56

Participants

Timeline

Start Date

February 1, 2018

Primary Completion Date

March 1, 2018

Study Completion Date

January 15, 2019

Conditions
ObesityInsulin ResistanceInsulin SensitivityType2 DiabetesVisceral Obesity
Interventions
COMBINATION_PRODUCT

Symbiter-Omega

Symbiter-Omega contains combination of flax and wheat germ oil (250 mg of each, concentration of omega-3 fatty acids 1-5%), supplemented with biomass of 14 alive probiotic strains: Lactobacillus + Lactococcus (6×1010 CFU/g), Bifidobacterium (1×1010/g), Propionibacterium (3×1010/g), Acetobacter (1×106/g) genera.

DIETARY_SUPPLEMENT

Placebo

Placebo

Trial Locations (1)

01601

Bogomolets National Medical University, Kyiv

All Listed Sponsors
collaborator

Taras Shevchenko National University of Kyiv

OTHER

lead

Bogomolets National Medical University

OTHER

NCT04201938 - Effect of Probiotic Co-administration With Omega-3 Fatty Acids on Obesity Parameters and Insulin Resistance | Biotech Hunter | Biotech Hunter